Open an account

Genocea Biosciences

GNCAQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About GNCAQ

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The firm has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.

Employees
74
Headquarters
Cambridge, Massachusetts
Listed
Feb 5, 2014
Sector
Health Care
Industry
Biotechnology
Website
genocea.com

GNCAQ key statistics

Market cap
59
Price-earnings ratio
—
Dividend yield
—
Average volume
4.93K
Volume
12.14K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0088
52 Week low
$0.00

Genocea Biosciences (GNCAQ) at a glance

As of Oct 9, 2026, Genocea Biosciences (GNCAQ) shares are priced at $0.00, giving the company a market cap of 59.

Volume so far is 12.14K shares, above the average of 4.93K shares a day.

Over the past year Genocea Biosciences has ranged from $0.00 to $0.0088, and now sits 0% of the way up that range.

Genocea Biosciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q1 FY22 it reported -$0.22 per share against an estimate of -$0.1875.

GNCAQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 40.4% on average.

  1. Q2 FY20: reported -$0.39 per share against an estimate of -$0.4172
  2. Q3 FY20: reported -$0.08 per share against an estimate of -$0.2493
  3. Q4 FY20: reported -$0.23 per share against an estimate of -$0.2142
  4. Q1 FY21: reported -$0.17 per share against an estimate of -$0.2039
  5. Q2 FY21: reported -$0.06 per share against an estimate of -$0.1875
  6. Q3 FY21: reported -$0.05 per share against an estimate of -$0.2034
  7. Q4 FY21: reported -$0.19 per share against an estimate of -$0.206
  8. Q1 FY22: reported -$0.22 per share against an estimate of -$0.1875

Similar companies

Companies in the same industry as Genocea Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.